Theravance, Inc is now called Innoviva. Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva's website at www.inva.com.
View Top Employees from Theravance, IncWebsite | http://www.thrxinc.com |
Ticker | INVA |
Revenue | $217 million |
Employees | 6 (0 on RocketReach) |
Founded | 1996 |
Address | 951 Gateway Blvd, South San Francisco, California 94080, US |
Phone | (650) 238-9600 |
Technologies |
HTML,
Network Solutions,
Proofpoint
+3 more
(view full list)
|
Industry | Investment Management, Drug Manufacturing & Research, Pharmaceuticals, Healthcare |
Web Rank | 6 Million |
Keywords | Innoviva, Innovivia, Innoviva Inc, Innoviva, Inc |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Theravance, Inc employee's phone or email?
The Theravance, Inc annual revenue was $217 million in 2024.
Theravance, Inc is based in South San Francisco, California.
The NAICS codes for Theravance, Inc are [3254, 32541, 325, 32].
The SIC codes for Theravance, Inc are [28, 283].